| Literature DB >> 35478704 |
Aslı Sogukpinar Onsuren1, Ufuk Utku Gullu2, Sevcan İpek3.
Abstract
Purpose: Children with acute rheumatic fever (ARF) or using depot-penicillin because of rheumatic heart disease (RHD) are prone to the risk of infective endocarditis (IE) and poor oral hygiene. This cross-sectional study aimed to investigate oral health experiences of a group of healthy children and a group of children with ARF or who were using depot-penicillin because of RHD (study group). Materials and methods: Medical and dental data of 86 children aged between 5-12 years were investigated in this study. Medical histories, decayed, missing, and filled teeth, plaque index, gingival index, toothbrushing frequencies, and the study and healthy groups' socioeconomic levels were recruited and examined.Entities:
Keywords: Acute rheumatic fever; cardiac disease; dental caries; oral health; rheumatic heart disease
Year: 2022 PMID: 35478704 PMCID: PMC9012219 DOI: 10.26650/eor.2022868100
Source DB: PubMed Journal: Eur Oral Res ISSN: 2651-2823
Methods for prevention from streptococcal infections in acute rheumatic fever (3). * In regions where rheumatic fever is not endemic, this period can be extended to 28 days. ** Given to those with penicillin allergies*** 15% of people with penicillin allergy also develop an allergic reaction to cephalosporins. IM: Intramuscular, PO: Peroral.
| Medicine | Application criteria | Dose/Method of administration | Primary protection time | Secondary protection time |
|---|---|---|---|---|
| Benzathine penicillin G | >27 kg | 1.200.000 unit, IM | Single-dose | Every 21 days* |
| 600.000 unit, IM | ||||
| <27 kg | Single-dose | |||
| Penicillin V | Primary protection | 3x250 mg/day, PO | 10 days | Everyday |
| Secondary protection | 2x250 mg/day, PO | |||
| Sulfadiazine or sulfisoxazole | >27 kg | 1x1 gr/day, PO | - | Everyday |
| <27 kg | 1x0.5 gr/day, PO | |||
| Erythromycin** | Primary protection | 20-40 mg/kg/day, 2-4 dose, PO | 10 days | Everyday |
| Secondary protection | 2x250 mg/day, PO | |||
| 1st generation cephalosporin*** | Primary protection | Variable by drug | 10 days | - |
The high risk of the patients with CHD (7).
| -Prosthetic cardiac valve or prosthetic material used for cardiac valve repair |
| -Prior IE |
| -Unrepaired cyanotic CHD, inclusive of palliative shunts and conduits |
| -In patients who have cyanotic CHD with residual defect or palliative residual defect |
| -In patients who have full-repaired CHD without residual defects up to 6 months after surgery |
| - In patients who have undergone transplantation and whose valve insufficiency continues |
Demographic information of the study participants.
| Variables | Study Group n= 43 | Healthy Group n= 43 | p value |
|---|---|---|---|
| Age (years ±SD) | 10.3±1.81 | 9.65±2.64 | 0.072 |
| Sex | |||
| Female | 29 (67.4%) | 21 (48.8%) | 0.080 |
| Male | 14 (32.6%) | 22 (51.2%) | |
| Toothbrushing frequency | |||
| more than 2 times a day | 10 (23.3%) | 20 (46.5%) | 0.024* |
| less than 2 times a day | 33 (76.7%) | 23 (53.5%) | |
| Socioeconomic status | |||
| Low | 13 (30.2%) | 16 (37.2%) | 0.778 |
| Medium | 25 (58.1%) | 22 (51.2%) | |
| High | 5 (11.6%) | 5 (11.6%) |
The medical diagnoses of the patients in the study group.
| Mitral Insufficiency (MI) | |
|---|---|
| Mild | 34 (79.1%) |
| Moderate | 4 (9.3%) |
| Severe | 2 (4.7%) |
| Aortic Regurgitation (AR) | |
| Absent | 19 (44.2%) |
| Mild | 23 (53.5%) |
| Moderate | 0 (0.0%) |
| Severe | 1 (2.3%) |
| Degree of Carditis | |
| First | 37 (86.0%) |
| Second | 4 (9.3%) |
| hird | 2 (4.7%) |
The oral health experiences of children with acute rheumatic fever or using depot-penicillin because of rheumatic heart disease and the healthy group.
| Caries index | Group | N | Mean ± SD | p-value |
|---|---|---|---|---|
| D | Study group | 43 | 5.05 ± 3.61 | less than .001* |
| Healthy group | 43 | 1.14 ± 1.92 | ||
| M | Study group | 43 | 0.33 ± 0.78 | 0.028* |
| Healthy group | 43 | 0.05 ± 0.21 | ||
| F | Study group | 43 | 0.14 ± 0.52 | less than .001* |
| Healthy group | 43 | 1.19 ± 1.40 | ||
| Dmft | Study group | 43 | 5.51 ± 3.81 | less than .001* |
| Healthy group | 43 | 2.37 ± 2.31 | ||
| D | Study group | 41 | 1.32 ± 1.71 | 0.029* |
| Healthy group | 35 | 0.57 ± 1.19 | ||
| M | Study group | 41 | 0.22 ± 0.82 | 0.154 |
| Healthy group | 35 | 0.03 ± 0.17 | ||
| F | Study group | 41 | 0.17 ± 0.77 | 0.158 |
| Healthy group | 35 | 0.46 ± 0.95 | ||
| DMFT | Study group | 41 | 1.71 ± 2.28 | 0.150 |
| Healthy group | 35 | 1.06 ± 1.59 | ||
| Gingival index | Study group | 43 | 0.89 ± 0.39 | 0.112 |
| Healthy group | 43 | 0.62 ± 1.03 | ||
| Plaque index | Study group | 43 | 0.87 ± 0.40 | less than .001* |
| Healthy group | 43 | 0.45 ± 0.41 |